BioMarin Pharmaceutical (BMRN) 10-Q2022 Q1 Quarterly report

Filed: 29 Apr 22, 1:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AAV, ago, analyzing, answered, arrangement, ascending, attack, aware, broker, carryback, Cellular, CJEU, companion, construction, coordinating, counsel, CTD, CTGTAC, delegate, deployment, diagnostic, digitalization, Eli, exacerbated, free, genome, genomic, gland, HAERMONY, hybrid, hyperoxaluria, importantly, inadvertent, indirect, insight, invasion, lease, Lilly, Lira, literature, liver, living, lump, MA, main, MAs, mentioned, molecular, necropsy, oncogenic, Overview, pattern, PIP, prejudgment, procure, promptly, quickly, ransomware, redosing, reinstated, repeated, resignation, reusable, Russia, salivary, sample, shortly, situation, streamlined, sum, swifter, talent, theoretical, tissue, toxicity, tumor, Turkish, turnover, Ukraine, unrecognized, variability, vector, version, view, younger

Removed: ABR, ANDA, anesthesiologist, antisense, applying, Article, asserted, avoidance, baseline, bioequivalent, branded, Brexit, bribery, call, capped, certify, challenged, closing, Colombian, commence, Commissioner, commonly, computed, cumulative, declined, demonstrating, Directive, disagree, divergence, divergent, divestiture, Duchenne, dystrophin, Dystrophy, element, Endocrinologic, Equivalence, exit, expiration, expression, FDC, fee, filer, finally, financed, fined, Firdapse, formulated, hearing, infringed, infringement, invalid, investigated, Kingdom, label, lifetime, lifted, line, listed, matured, median, metabolic, Muscular, NDA, NOL, noncompliant, notifying, November, observational, offered, oligonucleotide, open, Orange, paragraph, PDUFA, permitted, Peso, post, proceeding, proper, prophylactic, recommendation, recommending, registered, reiterated, replaced, requesting, resolved, Restoration, rollover, ruled, settled, settlement, stature, stay, suit, supervisory, supplement, supplemented, taxed, UK, undertaken, unrepatriated, unvaried, user, VIII, vosoritide, weakening, week, weight

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated BMRN transcripts

BMRN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

We, Jean-Jacques Bienaimé and Brian R. Mueller, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that BioMarin Pharmaceutical Inc.’s Quarterly Report on Form 10-Q for the period ended March 31, 2022, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of BioMarin Pharmaceutical Inc.


/s/ JEAN-JACQUES BIENAIMÉ
Jean-Jacques Bienaimé Chief Executive Officer

Date: April 29, 2022


/s/ BRIAN R. MUELLER
Brian R. Mueller Executive Vice President, Finance & Chief Financial Officer

Date: April 29, 2022

This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of BioMarin Pharmaceutical Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.